Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Opus Genetics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
IRD
Nasdaq
2830
opusgtx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Opus Genetics, Inc.
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
- Dec 19th, 2024 1:00 pm
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
- Dec 3rd, 2024 1:00 pm
Opus Genetics reinstated with a Buy at H.C. Wainwright
- Nov 14th, 2024 11:40 am
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Nov 12th, 2024 12:59 pm
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
- Oct 25th, 2024 4:00 pm
Scroll